Employee considerations when buying a business

When a business inherits employees during a transaction, it often takes on new and complex employment challenges. In this video, Torys litigators Sarah Whitmore and Irfan Kara take questions from Andrew Bernstein about how businesses can integrate new employees while mitigating their organization’s risk.

We discuss:

  • how to prevent wrongful or constructive dismissal claims
  • how to manage diversity, equity and inclusion risk when buying a business
  • why employment class actions pose a specific risk
  • why the decision on asset vs. share purchase is critical

Click here to see other videos in this series.


Andrew Bernstein (00:07): Hi, everyone. I'm Andrew Bernstein from the Torys Litigation Department, and welcome back to our series on commercial disputes. Today, I have my colleagues, Sarah Whitmore and Irfan Kara, both from Torys' Litigation Group. They are experts on employment law and that's today's theme. So hang on! You're in for a wild ride. Irfan, let me start with you. When a new entity takes over an existing business, there are usually decisions that need to be made with respect to employees of the business, whether they're offered employment with a new entity, whether the employment becomes redundant and needs to be terminated, whether a new role can be offered. What can businesses do to mitigate the risk of wrongful or constructive dismissal claims in those situations?

Irfan Kara (00:47): Thanks, Andrew. It really is an important consideration that we deal with quite often in the context of business transactions and the sale of businesses. And the considerations are a bit different depending on whether it's a share purchase or an asset purchase. And from a share purchase perspective, it's generally fairly simple because, you know, you've got the employer continuing on as the same entity generally, the obligations remain the same, service continues. You know, there may be some negotiated indemnities between the vendor and purchaser, but other than that, from an employment law perspective, everything kind of remains the same. If it's an asset purchase, the law has a bit more to say about this and it has more to say because the purchaser will have a choice as to whether or not they want to offer employment to the employees of the vendor. And if they do, there are a couple of things to take into consideration to mitigate that wrongful or constructive dismissal risk that you mentioned. And they really fall around two categories. It's comparable employment and continuous employment. From a comparable employment perspective, really the issue here is, is the offer of employment from the purchaser being made for a role and for a compensation that is substantially similar to what that employee was receiving with the vendor. And this is important from a risk mitigation perspective, because if that employee says, "No, I don't want to take that offer of comparable employment," then the vendor and purchaser can say, "Well they failed to mitigate their losses, and they have no common law claim for wrongful or constructive dismissal." And so that's a really important risk mitigation factor. The other side of it is continuous employment. And this is a big consideration, you know, that's tied to whether or not that asset purchase was considered a sale of business under the Employment Standards legislation. And if it was, and every employment standards legislation has its own kind of factors with respect to what constitutes a sale of business—it doesn't always constitute that—but if it does, then the law says that the employment would be continuous and this is a big factor for long-service employees, because if they reach a termination event at some point in the future, the liability for notice or pay in lieu of notice would be higher. So a consideration for sure to take into account for purchasers when they're dealing with commercial transactions involving employees.

Andrew Bernstein (03:00): Okay. Next question's for Sarah. Sarah, what if these issues arise with a group of employees? Is there a class action risk or is that too far-fetched?

Sarah Whitmore (03:11): So class action risk is always real when it comes to employment claims, I would say. And we've seen a significant rise in employment class actions over the years. Most have focused on claims for unpaid overtime or claims for employment benefits that are not being accorded to a group of employees as a result of an alleged misclassification. However, there are also examples of claims arising out of the scenario that Irfan just touched on through an asset purchase. And what happens in those cases is the group of employees maybe offered new employment with the purchaser, but the vendor might choose not to offer termination pay to that group of employees. And what would occur, or what could occur, would be a claim for a wrongful dismissal on behalf of the whole class. The issue with these claims, and something that potentially weighs in favour of defendants, is that they can be hard to certify. And the reason for that is a common defense to these claims, and Irfan touched on this, is that the employment simply continued to the new entity, and what's required to prove that is that the employees consented to the new employer, assuming responsibility for the vendor's liabilities, and that the new employer consented as well. When we talk about certification and what's required to actually start a class action, the question is, "Can these claims be prosecuted in common?" It's a procedural step that occurs before we even get to figuring out liability. And the class has to show that there are common issues that can be resolved without individual inquiries that will advance the claims for all class members. And what we've seen in the past is defeating certification of these claims by showing either individual employment contracts that need to be investigated, communications with individual employees that raise questions about their consent, and other individual factors. So the answer is yes, this can a class action risk, but it might not be the worst type of employment class action to face.

Andrew Bernstein (05:08): I don't think there's any good ones, but I take your point. So let's move on to a different subject—diversity, equity and inclusion. That's very much at the forefront of employers' minds today. So first question's for you, Sarah. Employers are being expected to do more to ensure that their workplaces are diverse, equitable and inclusive. And the law has followed suit. Should DEI be a significant consideration when making a commercial deal involving inheriting employees?

Sarah Whitmore (05:40): Absolutely. You know, one of the things that we've been talking about a lot with our clients recently is the benefits and the business kind of improvements of simply having a diverse workplace. And so that kind of goes without saying that's baseline and that's something that a purchaser wants to consider. But there are also litigation risks that go along with acquiring a business where the workforce is not diverse, or where there have potentially been issues around recruitment and promotion of diverse employees, because that's often what we see. As Irfan mentioned at the outset, a significant risk for purchasers is inherited or assumed liability that comes from taking on previous employers' employees. And the question that you need to consider when it comes to DEI is the Human Rights Code and whether there is a basis for discrimination across the existing workforce. And what we know and what the code tells us is that employers cannot discriminate on the basis of enumerated grounds. So that means no discrimination on the basis of race, sex, disability or other protective grounds. And that's tablestakes, that's well known to all of us. But what I think is coming out and what is more novel is claims that promotion or recruitment decisions have violated this right under the Human Rights Code. And what you want to think about when you're a purchaser is, were there policies in place or were there procedures for things like promotion decisions to try to really encourage diversity. And I think it's something that will only increase as the years go on. And it's something we need to be mindful of.

Andrew Bernstein (07:24): Thanks Sarah. Irfan, in light of the risks flowing from human rights liability, do we worry that this is just something that's going to happen before the Human Rights Tribunal, or is there any chance that this risk could manifest in a court proceeding?

Irfan Kara (07:39): So that kind of leads us back to class actions, right? And that's what we've seen in the last three to five years, is an increased prominence in EDI-type class actions. And it's important for employers to be aware of this and businesses to be aware of this in the context of commercial deals, because what we've seen previously is employers have been successful in defeating certification in these types of claims because they've said that, you know, from a jurisdictional standpoint, these types of claims are human rights matters, they're discrimination matters. And these are more properly before human rights tribunals and administrative bodies that have expertise in these areas.

Andrew Bernstein (08:10): Right.

Irfan Kara (08:10): But that's taken a bit of a change recently and courts are looking to actually take these on a bit more. And we've seen a couple of cases where the courts have agreed to frame these claims as breaches of contract. And so, you know, I've found that to be preferable to proceed by way of class action. So there are two really big-name cases in recent years. The one really big one is the Lewis class action in British Columbia against WestJet. And it's the sexual harassment and gender discrimination class action. And the main allegation here was that, you know, the class was exposed to systemic sexual harassment and it was framed as a breach of contract in essence that the class suffered a breach of contract, and the employer, WestJet, breached the employment contract by not providing a workplace that was safe from harassment and by not properly investigating claims for harassment and allegations of harassment. And so initially, the British Columbia Court declined to certify this because, again, it was a human rights matter, it's more properly before an administrative tribunal, and the expertise of those tribunals would give the class better access to remedies. Very, very recently, the British Columbia Court of Appeal actually overturned that and agreed to certify the class action on the basis that it was preferable to proceed by way of class action because this was a breach of contract claim. And so it really does emphasize the need to have a very proactive policy for employers with respect to EDI and harassment, and discrimination. And we don't know if this is going to be something that gets certified in Ontario, for example, where we have more stringent, now preferable, procedure requirements under the Class Proceedings Act, due to recent amendments. But it's still important for employers to realize that this is a type of claim that a class action may be certified against an employer for, you know, failure to meet contractual EDI requirements without any evidence of loss. And then the other really big one recently is the Thompson case, and that one is a proposed class action in very early stages involving hiring and promotion with respect to Black employees in the federal public service. It hasn't gone very far, but it's another big example and we'll see kind of where that goes in the coming months. And the last point on litigation risk, and Sarah touched on this a bit earlier, is that this doesn't just tie to things related to hiring. EDI covers the entire employment relationship, and it covers things from hiring, to retention, to performance reviews, internal processes all around from start to finish of the employment relationship. And so it's really important to think about those things in the context of a commercial deal that involves employees coming over.

Andrew Bernstein (10:44): Okay. Well, thank you very much to both you and Sarah. That was an incredible amount of insight in a short period of time. So that wraps up today's session and watch for the next one on the continuing series about commercial disputes. Thanks very much.

Le mois dernier, le Canada a publié sa première Stratégie industrielle de défense (la Stratégie), qui souligne l’engagement du Canada à développer une base industrielle de défense solide et à stimuler la croissance économique. Ces efforts pourraient aussi comprendre le renforcement de l’état de préparation à la biodéfense et aux contre-mesures médicales, ce qui pourrait constituer des débouchés pour le secteur canadien des sciences de la vie en raison de l’importance accordée aux capacités nationales en ce sens et de la nécessité d’atténuer les risques d’urgences sanitaires.

Développement de contre-mesures médicales au Canada

Comme indiqué dans les bulletins précédents, le quatrième pilier de la Stratégie est axé sur la « sécurisation des chaînes d’approvisionnement pour les intrants et les biens clés » par le renforcement de la production nationale et le stockage de ressources. L’accent est mis tout particulièrement sur les contre-mesures médicales, en précisant que nos « alliés ont établi un lien explicite entre l’état de préparation à la biodéfense et aux contre-mesures médicales et leur sécurité économique et nationale, en élaborant de nouvelles stratégies et de nouveaux mécanismes pour faire progresser ces travaux ». Les contre-mesures médicales désignent divers produits réglementés pouvant être utilisés pour protéger la population lors d’une situation d’urgence de grande ampleur, comme l’éclosion d’une maladie ou une attaque impliquant des armes chimiques, biologiques ou nucléaires. Il peut s’agir de vaccins, de médicaments thérapeutiques et produits biologiques, de dispositifs de tests diagnostiques, des équipements de protection individuelle ou industrielle, et d’autres dispositifs médicaux. Les contre-mesures médicales sont essentielles à la réduction et à l’atténuation des dommages lors d’une urgence de santé publique.

Exploiter les voies réglementaires mises en place lors de la pandémie de COVID-19

Pendant et après la pandémie de COVID-19, le Canada a mis en place plusieurs nouvelles voies réglementaires comme mécanismes d’accélération des approbations de produits médicaux, ce qui pourrait offrir au gouvernement des options pour déployer des contre-mesures médicales afin de faire face aux risques pour la santé publique. Au début de la pandémie, Santé Canada a émis diverses ordonnances provisoires pour permettre l’importation et la vente de médicaments et de dispositifs médicaux qui n’avaient pas eu l’approbation des voies réglementaires traditionnelles. Or, Santé Canada a plutôt fait confiance aux voies d’approbation réglementaire et de l’exemption de certaines exigences en homologation de produits des pays impliqués dans la transaction. Beaucoup de ces règles provisoires ont depuis été officiellement intégrées à la réglementation en vertu de la Loi sur les aliments et drogues et ont été appliquées bien après la COVID-19. Conformément au Règlement sur les aliments et drogues, Santé Canada tient à jour la Liste des maladies qui menacent la santé publique et utilisera une procédure d’autorisation modifiée pour les médicaments d’urgence de santé publique pouvant traiter les affections figurant sur la liste. De même, le Règlement sur les instruments médicaux a établi une liste d’instruments médicaux répondant à un besoin urgent de santé publique, ce qui permet à Santé Canada d’autoriser la commercialisation de ces instruments de manière accélérée. Ces outils réglementaires sont utilisés automatiquement quand une situation médicale présente un grand risque pour la santé publique au Canada et nécessite une action immédiate pour contrer ce risque.

Le rôle de la Stratégie dans le renforcement du régime réglementaire de la santé au Canada

La stratégie prévoit que le Canada adoptera une approche proactive en matière de planification en amont des crises sanitaires. Le gouvernement entend s’assurer que les produits médicaux sont déjà disponibles au Canada afin qu’ils puissent être distribués rapidement en cas d’urgence. D’autres modifications récentes au Règlement sur les aliments et drogues permettent de prépositionner au Canada tous les médicaments d’urgence en santé publique, ce qui signifie qu’ils peuvent être importés dans des installations d’entreposage canadiennes avant que leur mise sur le marché n’ait été autorisée. La Stratégie s’appuie sur ces fondements, en faisant référence à l’organisme existant Préparation aux crises sanitaires Canada (PCSC), un organisme opérationnel spécial au sein d’Innovation, Sciences et Développement économique Canada (ISDE), et à un nouveau Fonds des sciences de la vie, lesquels « collaborent avec des partenaires internationaux et de soutenir l’élaboration et la production de contre-mesures médicales ». PCSC supervise la Stratégie en matière de biofabrication et de sciences de la vie du Canada, qui vise à développer un secteur national des sciences de la vie fort et compétitif doté de capacités de biofabrication de pointe, en mettant l’accent sur la capacité à se préparer et à faire face aux futures priorités et crises sanitaires. Dans cette optique, il y aura des occasions pour les fabricants de nouer des collaborations de recherche et des accords commerciaux ou d’approvisionnement liés aux contre-mesures médicales financées par des programmes fédéraux.

Étroitement lié aux capacités nationales, le pilier III de la stratégie implique « Investissement ciblé pour renforcer un secteur canadien de la défense novateur », avec la promesse que le gouvernement fédéral « soutiendr[a] la recherche et le développement, protéger[a] la propriété intellectuelle, soutiendr[a] les petites et moyennes entreprises, investir[a] dans les compétences et la formation, et encourager[a] les exportations afin de créer un secteur de la défense agile et concurrentiel à l’échelle mondiale ». La nécessité de favoriser le développement de la propriété intellectuelle (PI) et la conservation des droits du Canada est mentionnée à plusieurs reprises dans la Stratégie. Par exemple, la Stratégie prévoit l’établissement de partenariats officiels avec l’industrie canadienne qui « [assureront] la propriété et le contrôle nationaux de la propriété intellectuelle (PI) et des capacités essentielles. » La Stratégie reconnaît l’immense talent des établissements canadiens et la précieuse recherche qui y est menée actuellement et qui est déjà financée par des subventions de recherche d’organismes tels que le Conseil de recherches en sciences naturelles et en génie et les Instituts de recherche en santé du Canada, et fait aussi référence à l’engagement de 1,6 milliard de dollars pour de nouveaux fonds de recherche dans le budget de 2025. Cette prise de conscience de la nécessité de promouvoir et de soutenir l’innovation au Canada laisse présager des possibilités de financement, notamment dans les domaines où le Canada accuse un retard en matière de production nationale et où des engagements d’investissement et de fabrication au Canada peuvent être pris.

Prochaines étapes

Dans les prochains mois, nous prévoyons que le gouvernement du Canada publiera d’autres directives et des mesures de suivi. L’équipe de défense des conservateurs poursuivra sa couverture de perspectives sur la défense au Canada en publiant une analyse supplémentaire pour donner des précisions sur l’incidence de la Stratégie sur de multiples secteurs.

Inscrivez-vous pour recevoir les dernières nouvelles

Restez à l’affût des nouvelles d’intérêt, des commentaires, des mises à jour et des publications de Torys.

Inscrivez-vous maintenant